Akers Biosciences (AKR) Share Price, News & Analysis

Company Overview

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Key Stats

• Today's Range: 57.50 to 57.50
• 50-Day Range: 57.50 to 57.50
• 52-Week Range: 23.50 to 491.60
• Volume: 262 shs
• Average Volume: 818 shs
• Market Capitalization: £21.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AKR Stock Analysis - Frequently Asked Questions

How have AKR shares performed this year?

Akers Biosciences' stock was trading at GBX 57.50 on January 1st, 2024. Since then, AKR stock has increased by 0.0% and is now trading at GBX 57.50.
View the best growth stocks for 2024 here.

How do I buy shares of Akers Biosciences?

Shares of AKR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akers Biosciences investors own include SandRidge Permian Trust (PER), Rite Aid (RAD), AT&T (T), BP (BP), Cross Timbers Royalty Trust (CRT), Solbright Group (SBRT) and Workhorse Group (WKHS).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: Trading
• Current Symbol: LON:AKR
• CUSIP: N/A
• CIK: N/A
• Web: www.akersbio.com
• Phone: +1-856-8488698
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 2.83

Sales & Book Value

• Annual Sales: £2.32 million
• Price / Sales: 9.31
• Cash Flow: GBX 63.76 per share
• Price / Cash Flow: 0.90
• Book Value: GBX 65.50 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 37,640,000
• Free Float: N/A
• Market Cap: £21.64 million
• Optionable: Not Optionable
• Beta: N/A